Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Heinecke

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Circulation|January 12, 2005
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndromeLars Eckardt, Vincent Probst, Jeroen P P Smits, et al.
Plos One|October 10, 2014
The NPM1 mutation type has no impact on survival in cytogenetically normal AMLFriederike Pastore, Philipp A Greif, Stephanie Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarraysKlaus H Metzeler, Annika Dufour, Tobias Benthaus, et al.
Trials|February 23, 2010
The Randomized Shortened Dental Arch study (RaSDA): design and protocolRalph G Luthardt, Birgit Marré, Achim Heinecke, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
The Lancet. Oncology|June 28, 2008
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancerMichael Thomas, Christian Rübe, Petra Hoffknecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
The Journal of Pathology|September 19, 2002
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTRChristopher Poremba, Bernhard Heine, Raihanatou Diallo, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Circulation|January 12, 2005
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndromeLars Eckardt, Vincent Probst, Jeroen P P Smits, et al.
Plos One|October 10, 2014
The NPM1 mutation type has no impact on survival in cytogenetically normal AMLFriederike Pastore, Philipp A Greif, Stephanie Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarraysKlaus H Metzeler, Annika Dufour, Tobias Benthaus, et al.
Trials|February 23, 2010
The Randomized Shortened Dental Arch study (RaSDA): design and protocolRalph G Luthardt, Birgit Marré, Achim Heinecke, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
The Lancet. Oncology|June 28, 2008
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancerMichael Thomas, Christian Rübe, Petra Hoffknecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
The Journal of Pathology|September 19, 2002
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTRChristopher Poremba, Bernhard Heine, Raihanatou Diallo, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Pageof 8